WEKO3
アイテム
メチオニンPETによる肺癌の重粒子線治療前後評価と予後判定研究
https://repo.qst.go.jp/records/62118
https://repo.qst.go.jp/records/6211845c7e2bb-a89f-4dfa-b941-319f789d655f
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-06-06 | |||||
| タイトル | ||||||
| タイトル | メチオニンPETによる肺癌の重粒子線治療前後評価と予後判定研究 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
吉川, 京燦
× 吉川, 京燦× 石川, 博之× 佐合, 賢治× 田村, 克巳× 松野, 典代× 神立, 進× 馬場, 雅行× 宮本, 忠昭× 鈴木, 和年× 辻井, 博彦× 吉川 京燦× 石川 博之× 佐合 賢治× 田村 克巳× 松野 典代× 神立 進× 馬場 雅行× 宮本 忠昭× 鈴木 和年× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose : The development of the novel carbon ion radiotherapy (CIRT) in treatment of different kind of cancers has resulted in the need for a way to accurately evaluate patient prognosis. We evaluated the effects of different factors on patients prognosis with lung carcinoma by comparing L-[methy1-11C]-Methionine (MET)uptake in Positron Emission Tomography (PET) Scan. Experimental Design : MET-PET scan was performed in 66 patients before and Post-CIRT. Patients were followed for 3.5 to 53 months (mean: 24.1 months). Tumor and suspected lymph nodes MET uptake were measured with a semi-quantitative Tumor-to-muscle ratio (TMR) and lymph node-to-muscle ratio (LMR). TMR, LMR and relevant clinical parameters were entered into univariate and multivariate survival analysis. The relationship between distant metastasis (D.M), number of lymph nodes (LN) before CIRT and percentage of change uptake (residual tumor index:RTI) with patients survival, were also analyzed. Results : The overall median survival time was 20.0 months. There was no statistically significant difference of survival between before and Post-CIRT TMR and its changes by using multivariate analysis. Patients with a baseline maximum LMR of < 4.4 had a significant better survival than patients with a maximum LMR of > 4.4 (P=0.001). Patients with three suspected LNs or less, had a better survival than more than three LNs (P=0.002). A significant difference on survival rates were found between patients who showed D.M during first six months of follow-up or later and patients with out D.M (P=0.003 and 0.005 respectively). Conclusions: CIRT is very effective treatment for original tumor in Lung carcinoma. The most important prognostic factors are Max LMR, number of LN and D.M. But TMR and LMR can estimate the possibility of finding D.M and local recurrence. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | H18年度HIMAC共同利用研究成果発表会 | |||||
| 発表年月日 | ||||||
| 日付 | 2007-04-10 | |||||
| 日付タイプ | Issued | |||||
